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Some medicines are available in doses that are not suitable for a specific population group 
and therefore manipulation of the existing medication is undertaken in order to obtain the 
required concentration of that medication. The groups affected by this include paediatrics, 
adults who are unable to swallow (such as, geriatric patients); those who are fed using naso-
gastric tubes; and the terminally ill. Studies on the practices, frequency and extent of 
extemporaneous compounding have been undertaken in other countries such as New 
Zealand, Australia, United Kingdom, United States of America, the Netherlands and 
Mexico. No published data currently exists for South Africa. Extemporaneous compounding 
studies are essential for improving the care of patients particularly in South Africa with its 
complex and unique challenges.  
 
Aim: 
The aim of this pilot study was to explore the extemporaneous compounding practices in a 
South African public sector setting.  
 
Methods: 
This was a pilot study using a cross-sectional descriptive design. Purposive sampling was 
used to sample both the hospitals and the pharmacists. A self-administered close-ended and 
open-ended questionnaire was designed to collect information from willing pharmacists for 
exploring the compounding practice processes. All the batch records from April 2008 to 
March 2009 were purposively sampled for frequency and extent of compounding to obtain 
information on dosage form, medicine classification and route of administration. The 




Fifty-nine questionnaires were distributed to tertiary hospital pharmacy personnel, of which 
25 were returned (a 42.37% response rate). The main findings were that almost all of the 
pharmacists (96%) reported receiving compounding skills training and 60% of the 
respondents confirmed that the expiry date was personally developed. There was no proof of 
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records being kept on the regular calibration of electronic weighing balances (76%) and 
maintenance (72%) despite the fact that documentation for compounding comprising of 
manufacturing batch records (80%), as well as compounding formula and procedures (72%) 
are mostly kept. The maintenance of electronic weighing balances was in the most 
instances, not carried out (64%). A logbook of all compounded medicines was commonly 
not kept (64%). A key finding was that there was limited training in aseptic technique (3%), 
which, if not applied correctly, could result in contamination of compounded products. 
 
About 691 batch records were reviewed for the study period. The most compounded 
medicines were dermatologicals (46.60%), with, creams and ointments totalling 33.0% and 
13.60%, respectively. The most compounded product was Betamethasone cream (27.9%) .   
 
Conclusion:  
The findings suggest that there seem to be insufficient skills within the tertiary hospital 
pharmacy staff for small scale compounding. Documentation on equipment calibration and 
maintenance was not available in most cases.  The findings of this pilot study highlight the 
need for further such studies across South Africa to identify and improve extemporaneous 
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CHAPTER ONE: INTRODUCTION 
1.1 Introduction 
This chapter provides a background to the need for the study and the aim and objectives of 
the study. It also describes the novelty and significance of the research that was undertaken. 
1.2 Background to the study 
The lack of appropriate dosage forms, dose or strength for specific groups of patients is 
widespread and has resulted in the need for extemporaneous compounding worldwide 
(Brion et al., 2003; Calvalho et al., 2008; Giam et al., 2011). In other cases, 
sensitivity/allergy to the excipients and preservatives, shortage, discontinuation of 
medicines, special combination or orphan medicines contribute to the need for compounding 
(Sellers and Utian, 2012). Examples of the groups or individual patients catered for by 
extemporaneous compounding are paediatrics, geriatrics or those adults who have difficulty   
swallowing solid dosage forms and those for whom medication is administered in a liquid 
form through naso-gastric tubes due to poor swallowing reflexes necessitating 
extemporaneous compounding (Standing and Tuleu, 2005).  
 
Extemporaneous compounding is, therefore, usually prepared from commercially available 
or existing solid dosage forms (Brion et al., 2003; Haywood and Glass, 2007; Spark, 2014), 
in a dose or dosage form (Haywood and Glass, 2007) not suitable for the above-mentioned 
groups with the aim of providing drug formulations that are effective and well-tolerated by 
patients (Nahata and Allen, 2008), or may entail the crushing of tablets or dispersing the 
capsule contents into a suitable liquid dosage form which may require the inclusion of 
excipients such as flavourants (Haywood and Glass, 2007). These mask the bitter taste. A 
suspending agent, which is required to facilitate and distribute the crushed tablets into the 
solution for dose uniformity, is also added so that the tablet excipients that are usually 
insoluble in water are suspended. Colorants, preservatives and viscosity enhancers are other 





Giam and McLachlan (2008) define extemporaneous compounding as “extemporaneous 
preparation, mixing, packaging or labelling of a medicine as the result of a practitioner’s 
prescription of medicine in order to meet an individual patient’s need”. In this study 
extemporaneous preparation is defined as products made or compounded in a pharmacy on a 
small scale to meet patients’ specific requirements within all age groups, or a tailored 
therapy for a specific patient (Brion et al., 2003; Gross, 2005; Schultz, 2007). The practice 
of extemporaneous compounding for this study involved a small scale manufacture of 
preparations, using raw materials or commercially available dosage forms to reformulate a 
suitable dosage form at an appropriate strength for a specific patient of any age group. The 
practice of extemporaneous compounding is necessary to ensure that paediatrics and adult 
patients receive appropriate formulations of medicines to meet their specific requirements 
(Brion et al., 2003). Extemporaneous compounding, therefore, has diverse applications and 
is critical in patient health care and optimizing treatment outcomes. 
 
Whilst it is widely used, numerous concerns and challenges pertain to this compounding 
practice. One of the concerns is lack of standardized ways of preparing different 
compounded preparations for different patients. In other words, there is limited stability data 
for numerous preparations that are frequently subjected to extemporaneous compounding 
(Nahata et al., 2000). Since the stability of such preparations is unknown, this may lead to 
formulations being given a short or long expiry date. Globally, the pharmaceutical services 
do not prescribe standard protocols for extemporaneous preparations and, as such, there are 
high risks with extemporaneous compounding. In a 2006 survey conducted by the Food and 
Drug Administration (Food and Drug Administration, 2006), some of the challenges were 
the improperly compounded, adulterated medicines having the potential to cause significant 
harm to patients. This survey emphasized that without strict observance of Good 
Manufacturing Practice (GMP) guidelines, it is possible to have miscalculations of the 
respective quantities of each ingredient and this could be problematic, especially where the 
system and processes are not tightly regulated. The survey indicated that there were 
inadequate standards related to compounding, with no auditing against those standards and 
these had posed a high risk of harm to patients’ health. Another concern was the global lack 
of pharmacists in most hospitals, and this puts pressure on those who were employed due to 
the additional workload. Another study pointed to poor compounding techniques by 
untrained compounding personnel, leading to mishaps, such as the anti-cancer drug case in 
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2001 in Kansas City where 158 chemotherapy doses for 34 patients were diluted to a lower 
concentration. This affected 98 000 prescriptions given to 4200 patients whose lives were at 
risk of wrongful death which involved 400 physicians (Oceania Health Consulting, 2005). 
In the same year in California, one pharmacist was linked to three deaths from meningitis as 
a result of bacterial contamination of a compounded Betamethasone injection that was 
administered to 38 patients (Oceania Health Consulting, 2005). In Atlanta in 2002, four 
patients were hospitalized, with two falling into a coma, after swallowing a compounded 
Thyridoxine hormone which was 1000 times more concentrated than the prescribed strength 
(Oceania Health Consulting, 2005). These tragedies raised concerns regarding 
extemporaneous compounding practices and their limitations. The global lack of 
documentation and standardized formulations poses a high risk to patients as there may be 
variations in manufacturing methods used and also the excipients used may differ greatly 
and their effect on the stability and quality of the compounded medicine cannot be 
guaranteed. The stability testing guidelines for instance, may also help in producing 
medicines of stable, efficacious and acceptable quality.  
 
Various countries such as New Zealand (Kairuz et al., 2007a), Australia (Feldschuh, 2008), 
the United Kingdom (Stewart et al., 2007), the United States of America (Treadway et al., 
2007), the Netherlands (Giam and McLachlan, 2008) and Mexico (Flores-Perez et al., 2008) 
have undertaken studies to determine the skills of staff compounding medicines, as well as 
the frequency and extent of extemporaneous compounding practice. Compounding did 
decline from 10-15% to 5% in the Netherlands in the 1990s (Buurman et al, 2003). The 
compounding practice is also confirmed by the retrospective survey conducted in 2007 by 
Kairuz et al. in the two New Zealand hospitals where the findings revealed the most 
frequently compounded preparations to be Solatol for neonates and infants, Labetolol, 
Clonidine for infants and children, and Diazoxide for infants. About 0.5% of all 
prescriptions were extemporaneously compounded in England in 2001, including off-label 
medicines (Donnelly et al., 2008). Buurman et al. (2003) in their study reported a frequency 
of 3.4% for compounded prescriptions dispensed by the Dutch community pharmacy.  






Since compounding has shown to be occurring, it is the responsibility of pharmacists in the 
hospital settings to assure the quality of all compounded preparations (Agharowa et al., 
2013). This is largely due to their professional obligations and training, enabling them to 
undertake extemporaneous compounding by ensuring that all formulations are in accordance 
to acceptable compounding standards (Lowley and Jackson, 2008). Compounding skill is a 
required competency practice for registered pharmacists in many countries; hence, quality 
assurance (QA) necessitates the use of suitably trained personnel to produce a safe and 
quality product (Kairuz et al., 2007a). Compounding practice is generally based on the 
following standards:  1) the hospital pharmacy personnel or the type of staff who are 
involved in compounding, 2) training methods, 3) documentation, 4) compounding 
formulation and the source, 5) how expiry date is determined, 6) what equipment is used 
and 7) the reasons for compounding. Clear Standard Operating Procedures (SOPs) should be 
in place for major items of compounding and equipment. The safety and quality of 
extemporaneously compounded preparations should be ensured by compounding a product 
with an expected potency and its characteristics maintained to the time of expiry. Safety 
risks may, therefore, be minimized through skill, training and knowledge on QA procedures.  
 
Whilst aspects of extemporaneous compounding have been studied and reported for the 
countries above, such as the frequency and extent of the practice, formulation optimization 
or development of regulatory policies, there are no such published studies to date reported 
from South Africa on the subject matter, except those published studies in South Africa by 
de Villiers (2005) and Tetty-Amlalo (2005) at the Universities of Potchefstroom and Rhodes 
respectively. Their studies were on extemporaneous compounding which were, however, 
focused on the optimization of compounded formulations and not on establishing the status 
of extemporaneous compounding. Labuschagne et al. (2005) presented a poster at the 26th 
Annual Conference of the Academy of Pharmaceutical Sciences of South Africa on the 
stability of the formulation of novel drug dosage forms of antiretroviral drugs.  Aspden et al. 
(2011) presented a poster to determine the methods of extemporaneous compounding 
teaching methods in five countries: South Africa, New Zealand, Canada, Australia and the 
United Kingdom. In Jamaica, Harries et al. (2011) presented a poster on optimization and 
the compounding practice in the same country. In South Africa there are complex health 
challenges, various groups requiring age-appropriate medicines compounded 
extemporaneously for improving health care. By documenting such practices, locally 
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developed and locally relevant Standard Operating Procedures and formulations can be 
developed. 
1.3 Aim and objectives of the study 
1.3.1 Aim of study 
The aim of this pilot study was to explore the extemporaneous compounding practices in a 
South African public sector setting.  
 
In order to achieve the above aim, the objectives of this pilot study were: 
1. to assess the skills set and capacity of the staff compounding medicines in the tertiary 
hospital pharmacy in the Polokwane Municipality; 
2. to determine the most common dosage form and product being compounded in the tertiary 
hospital pharmacy in the Polokwane Municipality. 
1.4 Significance of the study 
The findings of the study will contribute to the following: 
 
• Identification of a potential need for the development of guidelines and Standard Operating 
Procedures (SOPs) for extemporaneous compounding in hospitals. 
• Identification of areas of skills development in pharmacy personnel involved in 
extemporaneous compounding. 
• Identification of a potential gap in the education of pharmacists at an undergraduate level. 
• The need for further research in this area. 
1.5 Novelty of the study 
Extemporaneous compounding studies in several countries such as New Zealand, Australia 
and the Netherlands have been reported to date (Kairuz et al., 2007b). However, in South 
Africa with its complex health challenges and various groups requiring specially 






1.6 Overview of the dissertation 
This section of the report seeks to highlight the contents of each chapter. 
 
CHAPTER ONE: INTRODUCTION 
The chapter gives an orientation to the study, which includes the background to the need for 
the study, the aims and objectives and the significance of the study. 
 
CHAPTER TWO: LITERATURE REVIEW 
This chapter contains a detailed literature review on the theoretical aspects of 
extemporaneous compounding and includes an identification of such studies reported 
globally.  
 
CHAPTER THREE: SUBMITTED MANUSCRIPT 
The chapter presents the results of the study in the form of a submitted article on 
determining the skills of the pharmacists in preparing compounded preparations as well as 
the frequency and extent of compounding in order to assess compounding standards. 
 
CHAPTER FOUR:  CONCLUSIONS AND FUTURE STUDIES 
In this chapter, conclusions are generated from the main findings of the study and their 
significance is highlighted. Limitations of the study and recommendations to improve or 





CHAPTER TWO: LITERATURE REVIEW 
2.1 Introduction 
This chapter presents an appraisal of the literature on extemporaneous compounding. It 
focuses on its applications and current concerns. The chapter also discusses various studies 
undertaken globally to identify the frequency and the extent of extemporaneously 
compounded medicines as well as the standards thereof.   
 
Most commercial  medicines are unavailable in dosage forms that are suitable for specific 
groups of patients (Nahata et al., 2000). As such, extemporaneous compounding is 
necessary to provide health care to population groups of patients such as geriatrics and other 
adults who are not able to swallow solid dosage forms such as tablets and capsules due to 
swallowing difficulties (Argoff and Kopecky, 2014). Another group benefitting from this 
practice are paediatric patients (Kairuz et al., 2007a; Aquilina, 2013). Regulatory bodies set 
the standards for regulating the manufactured medicines (Oceania Health Consulting, 2005) 
but no such standards exist for extemporaneously compounded medicines (Lowey and 
Jackson, 2008). The lack of quality control measures increase the risks associated with 
compounding by putting patients at risk (McCague et al., 2012) such as contamination in  
medicines; more so, as there are no quality control tests done to assure the safety and quality 
of those medicines (Gudeman et al., 2013). Pharmacists are health care professionals who 
receive formal training in compounding medications and are licensed to dispense (Eley and 
Birnie, 2006). This literature review reveals the importance of the abilities and skills 
possessed by the pharmacists to minimise risks to patients. The keywords that were used as 
search terms were: extemporaneous compounding; compounding; and compounding 
practice, and the search engines that were incorporated into the review were: Google; 
Google Scholar; Web of Knowledge; Science Direct; Pubmed  up until March 2015. It was 
hoped that by using Google and Google Scholar any unpublished studies from South Africa 
would be captured. 
2.2 History of extemporaneous compounding and standard definition 
Extemporaneous compounding practice dates back to the ancient biblical times where 
priests or medicine men administered to the sick portions of syrups as they carried out the 
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religious rituals (Cox Pharmacy Wellness Centre, 2005). In the 9th century, the first 
compounding evidence was recorded in Baghdad and the science subsequently spread to 
Europe (Cox Pharmacy Wellness Centre, 2005).  According to Riley (2004), “compounding 
has been a part of pharmacy practice for over 4000 years when the pharmacist applied the 
art of selecting, extracting and preparing medicines from vegetable, animal and mineral-
substances in an acquirement that must have been almost as ancient as man himself on 
earth”.  
According to Riley (2004), “when the first United States Pharmacopoeia was published in 
1820 in the United States, pharmacists still compounded most prescriptions. In the 1920s a 
“broad knowledge” of compounding was still necessary for 80% of prescriptions 
dispensed”. In the 1930s and 1940s, 60% of the medications were compounded. There was a 
decline in the 1950s and 1960s due to the advent of commercial manufacturing of medicines 
(Riley, 2004). Another steady decline was observed in the 1980s due to the emergence of 
the compounding companies such as Paddock Labs and Spectrum (Riley, 2004). 
Extemporaneous compounding has been the traditional role of the pharmacist which 
declined with the availability of manufactured medicines (Chowdhury et al., 2012). While 
pharmacists no longer compound individualised prescriptions to the extent they did in the 
1930s and 1940s, they still compound commercially available medicines (Kolling and 
McPherson, 2013). For example, a pharmacist may be requested to prepare an oral liquid 
solution for an infant from crushed tablets or powder, in a suitable base, in the absence of an  
appropriate dosage form or strength for children, and these are often referred to as 
extemporaneously prepared medicines and the practice occurs internationally (Patel et al., 
2011; Arghahowa et al., 2013). 
The practice of extemporaneous compounding, therefore, describes “small scale 
manufacturing which entails the manipulation by the pharmacists of various medicines 
(active) and chemical ingredients using traditional compounding techniques to produce 
suitable medicines (dosage form) when the commercial forms that are available are 
inadequate or cannot be used as formulated” (Brion et al., 2003; Winfield, 2004; Nahata and 
Allen, 2008;). These extemporaneously compounded preparations are prepared in a 
pharmacy in response to an immediate request by a prescriber,  in limited quantities for an 
individual patient (Aquilina, 2013), through a medical prescription. In this study 
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extemporaneous preparations are defined as products made or compounded in a pharmacy 
on a small scale to meet specific patients’ requirements of all age goups.  
2.2.1 Terminology and concepts of extemporaneous compounding  
In this section terminology and concepts of extemporaneous compounding are presented.   
In the United States, the Food and Drug Administration (FDA) regards traditional pharmacy 
compounding as “the extemporaneous combining, mixing, or altering of ingredients by a 
pharmacist in response to a physician’s prescription to create a medication tailored to the 
specialized medical needs of an individual patient” (FDA, 2006). Schultz (2007) defines 
extemporaneous medicines as products made or compounded in a pharmacy on a small scale 
to meet a specific patient’s specific requirements (all age groups) or a tailored therapy for a 
specific patient. In this study, the practice of extemporaneous compounding involved a 
small scale of manufacture of preparations, using raw materials or commercially available 
dosage forms to reformulate a suitable dosage form at an appropriate strength for a specific 
patient of any age group with a specific condition.   
 
Table 2.1 below shows the definition of extemporaneous compounding terms that are used 
interchangably. 
 
Table 2.1:  Terminology commonly used to describe extemporaneous compounding 
Term Description Reference 
Extemporaneous compounding “The reformulation of 
medicines into a suitable 
dosage form for a particular 
patient”. 
Kairuz et al., 2007a 
Compounding “The preparation, mixing, 
packaging or labeling of a 
medicine as the result of a 
practitioner’s prescription 
medicine” in order to meet an 
individual patient’s need”. 




Term Description Reference 
Extemporaneous preparation “Preparations prepared from 
commercially available solid 
dosage forms with the aim of 
providing access to, among 
others, age-appropriate 
medicine formulations that are 
effective and well-tolerated by 
patients”. 
 
Haywood and Glass, 2007 
Nahata and Allen, 2008 
 
2.3 Importance and application of extemporaneous compounding  
Extemporaneous compounding practice has a long history (Chowdhury et al., 2012). 
According to the WHO, the rational use of medicines, which, in New Zealand and Australia 
has evolved into the Quality Use of Medicines (QUM),) demands that appropriate medicines 
of quality, safety and efficacy be accessible to all patients at the right time, cost, suitable 
dose and dosage form (Kairuz et al., 2007a). While the different federal approved medicines 
meet the therapeutic needs of most patients (Sellers and Utian, 2012), there are 
circumstances in which extemporaneously compounding plays a vital part in medical care 
(Treadway et al., 2007). The compounding practice improves the health of different patient 
population groups who are unable to swallow solid dosage forms. Since “oral drug delivery 
using solid dosage forms such as tablets and capsules is the most common and popular route 
of administration to deliver medications into the body” (Manrique et al., 2013; Lau et al., 
2015), some patient population groups might be deprived of access to the potential 
therapeutic benefits of medicines (Manrique et al., 2013).  
Therefore, extemporaneous compounding caters for the availability of medicines to 
geriatrics and other adults who are unable to swallow solid dosage forms due to poor or 
compromised swallowing reflexes (Argoff and Kopecky, 2014). Another patient population 
group benefitting from this practice of extemporaneous compounding is paediatrics (Argoff 
and Kopecky, 2014) as most solid dosage forms are usually available in adult strength and 
accurate paediatric dosing is often not possible using tablets and capsules (Kairuz et al., 
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2007a). Another diverse application of extemporaneous compounding is in dermatological 
or palliative care (Gross, 2005), where a combination of topical dermatological medicines 
are custom-made in a limited quantity to meet the clinical needs of an individual patient 
(Aquilina, 2013). Extemporaneous compounding practice is necessary as part of the health 
system to ensure availability of a prescribed drug at the right time at an affordable price to 
special-need and specific patient populations (Milner and Bruss, 2008), who lack access to 
approved medicines and formulations (Sosnik et al., 2012).  
Although compounded medicines are prepared in limited quantities for individual patients, 
according to Aquilina (2013),  bulk compounding is a common practice in the National 
Health Service in countries like England, and such a practice violates both the pharmacy and 
the medicine acts for human use (Gross, 2005). There are again those community 
pharmacies in the United Kingdom (UK) which primarily dispenses ‘specials’ as observed 
by Calvalho and Tuleu (2008). Another common compounding practice in European 
countries such as Portugal, Spain and Germany is compounding made for stock in 
anticipation of a prescription (Gross, 2005). Locally, there are no published records showing 
the occurance of such practices.   
2.4 Risks and concerns associated with extemporaneous compounding 
Although the compounding practice shows global prevalence, extemporaneous 
compounding activities carried out in pharmacies today bears the highest risk and poor 
quality has often proven to be the evidence to support the occurance of risks (Lowley and 
Jacson, 2008). In other words, extemporaneous compounded preparations generally “lack 
studies to document stability, bioavailability, pharmacokinetics, pharmacodynamics, 
efficacy and safety” (Sellers and Utian, 2012), “leading to increased toxicity, e.g. crushing 
an extended-release solid dosage form may lead to dose dumping; undesirable side effects 
and decreased efficacy. Furthemore, crushing an enteric coated tablet may result in 
destruction of the active ingredient in the acidic environment of the stomach and 
unpalatability, resulting in poor patient compliance” (Sellers and Utian, 2012).  
There is a lack in previous studies to document stability, bioavailability, pharmacokinetics, 
pharmacodynamics, efficacy and tolerability (Patel et al., 2011), and the safety of 
compounded medicines may be compromised. There is also elevated risk in newborn infants 
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because they are more likely to be predisposed to adverse drug reactions due to their 
physiological immaturity (WHO, 2007). In previously studies by Glass and Haywood 
(2006), looking into considerations when preparing a liquid dosage form from the 
commercialy available medicine, the findings were that formulations may also contain 
preservatives; an excipient considered to be largely inert in adults could lead to life 
threatening toxicity in paediatrics when multiple doses of medications with the same 
preservative are employed.  Children are not small adults hence their physiological 
development and bioavailability of medicines is different from that of adults. Therefore the 
direct extrapolation of the clinical data to predict the medicine absorption, distribution, 
metabolism and elimination cannot be done accurately from adult clinical data (Standing 
and Tuleu, 2005; Barnes, 2008).  Such inaccurate dosing can put children’s lives at risk 
either by underdosing or overdosing which can expose paediatric patients to toxic effects of 
the medicines (Barnes, 2008). 
Furthermore, depending on their age many children are unable to swallow a solid whole 
tablet or capsule, even when given training on how to do so (Standing and Tuleu, 2005). 
There is again a problem in dosing accuracy as dosing is often based on body weight. This 
was observed by the first comprehensive summary reviewed by Glass and Haywood (2006) 
of tablets often cut into smaller segments in the ward to obtain appropriately sized dosage 
units for children. Their observation was that "those segments cannot be cut with great 
accuracy of dose. This is contradictory to the findings of Brion and colleagues (2003) who 
identified it as an alternative way to prepare medication for the paediatric population. 
Standing and Tuleu (2005) cited an audit at Great Ormond Street (GOSH) in London (UK), 
one of the seven specialist pediatric hospitals in England, where it was found  that 
“manipulations such as tablet cutting, tablet crushing and opening of capsules was necessary 
to administer 26% of oral doses given to in-patients, although the data was not published”. 
According to Standing and Tuleu (2005), splitting tablets leads to dose inaccuracy, and 
crushing the tablets can affect absorption and cause therapeutic failure. 
In some instances, the risks associated with compounding may be fatal to the point of 
causing deaths. Large scale compounding may adversely affect many patients due to errors 
which might occure in the process (Gudeman et al., 2013). For example, in the most recent 
study conducted by Staes et al. (2013), the findings in the fungal miningitis outbreak caused 
by medicines compounded by the New England Compounding Center indicated that there 
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were  “11 infectious outbreaks from contaminated compounded preparations involving 207 
case-patients with 17 deaths between 2000 and prior 2012” (Staes et al., 2013). Staes and 
colleagues reported “the 2012 meningitis outbreak increases totals of death cases to almost 
5-fold”.  Their findings further determined that “the state health agencies identified 490 
case-patients with serious fungal infections, including meningitis, stroke or other central 
nervous system-related infection and joint infections, where 34 case-patients died and the 
outbreak involved 19 states, and that the Compounding Centre estimated that approximately 
14 000 patients received injections from 3 lots of methylprednisole”. 
Other examples include the “peppermint water case”, cited by Lowey and Jackson (2008), 
where “the use of concentrated chloroform-water led to the death of a child. This case 
highlighted the dangers of potent ingredients and calculation errors, particularly where the 
strength of one or more ingredient is stated in a historical or non-standard fashion”. Similar 
reports have originated from the US, with the death of a child from a super potent 
imipramine liquid, and a five-year-old child who received a 1000-fold overdose of clonidine 
(Glass and Haywood, 2006; Lowey and Jackson, 2008). “It has been estimated that more 
than 40% of doses given in paediatric hospitals require compounding to prepare a suitable 
dosage form since crushing a tablet and/or sprinkling the contents of a capsule over food or 
mixing it in a drink may lead to errors in preparation or delivery of doses” (Patent google, 
2011). The formulation of paediatric medicines therefore demands more than simply cutting 
a tablet into half, or suspending the capsule’s contents in water to get the correct dose for 
administration to this group. 
Other concerns associated with extemporaneous compounding practice are that there is very 
little clinical data and evidence-based information on optimal dosages, frequency of dosing, 
efficacy and safety in pediatrics when new drugs reach the market. While the World Health 
Organization and other statutory bodies demand that an appropriate medicine be made 
available in an appropriate dosage form and the correct quantity be dispensed at the right 
time, and that it be taken in the right dose for the length of a prescribed treatment period, the 
lack of evidence for medicines for some groups of patients is widespread. Such lack has 
sparked the initiation of this extemporaneous compounding practice worldwide (Brion et al., 
2003; Giam et al., 2012). To ensure the appropriate preparation dosage form and dosing 
regimen the skills and judgement of both the pharmacist and the physician become critical.  
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These risks raise concerns regarding extemporaneous compounding practices and their 
limitations which are outlined below (Oceania Health Consulting, 2005). 
2.4.1 Concerns and limitation of extemporaneos compounding 
a) Limited validated stability data 
There are no reports published or documented in any form of stability of extemporaneous 
preparations. The stability data is lacking for numerous medicines that are frequently 
subjected to extemporaneous compounding. Pharmacists are performing a broad range of 
extemporaneous compounding activities from oral solutions to powders as highlighted by 
Crawford and Dombrowski (2008) in their survey. It is apparent that there is a need for 
documented stability and other information on extemporaneous medicine formulations 
(Kairuz et al., 2007a). 
b) Short expiry date 
The stability of extemporaneous preparations may be unknown, leading to these 
formulations being given an untested shelf-life. Further, environmental conditions differ in 
countries, thus necessitating stability studies congruent with realistic storage conditions of 
the extemporaneous preparation.   
c) Shortage of pharmacists 
Compounding is time consuming. Due to the global shortage of pharmacists in the country, 
(Buurman et al., 2003), the current pharmacists find themselves pressurized by heavy 
workloads, making compounding a challenge in most hospitals. In 2004 and 2005, Butler 
conducted a pilot Dispensing Service Research Project in 29 pharmacies in South Africa. 
According to Butler (2006) regarding the workload of pharmacists in the activities of 
dispensing, these are the differences in timelines: it takes 8.7 minutes for a pharmacist to 
dispense complex and uncomplicated medicines (complex counselling with all dispensing 
steps included) compared to 18 minutes 45 seconds per complicated (compounded) 
medicine item, the longest time being the interpretation evaluation phase which is the first 
phase of dispensing. 
d) Untrained personnel 
Possession of a qualification as a pharmacist or pharmacist’s assistant does not necessarily 
imply adequate skills to carry out all functions efficiently and independently. Additional in-
service training may be required in specific areas (FDA, 2006). There is a potential for poor 
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compounding techniques, leading to cross-contamination and human error with untrained 
personnel (FDA, 2006).  
e) Quality assurance procedures 
The essence of quality assurance is to provide proof of what is claimed to be taking place or 
supposed to be taking place in terms of the processes in the extemporaneous compounding 
practice. In South Africa compounding is regulated by the South African Guidelines of 
Good Manufacturing Practice.  These guidelines specify minimum standards required to 
maintain the quality of medicines and to ensure patients’ safety. They are standard 
requirements considered by the Medicines Control Council’s (MCC) quality control 
procedures to ensure medicines’ quality, while pharmacists are governed by the South 
African Pharmacy Council (SAPC). The MCC, however, is not in a position to enforce 
compliance by compounding hospitals and pharmacies.  The SAPC does not have a large 
inspectorate workforce to assess the quality of extemporaneously compounded preparations 
made on a small scale at the hospital pharmacies based on the specified standard of quality 
as a regulatory body. In the US, the United States Pharmacopeia (USP) and the American 
Society of Health System Pharmacists (ASHP) have developed guidelines on compounding 
procedures for the pharmacist in an attempt to help raise the standards of compounding and 
prevent the risk of patient harm. There are no such guidelines and sets of standards in South 
Africa.  Milne and Bruss (2008) suggested that internationally harmonized guidelines for 
extemporaneous compounding to supplement formulation needs are required. 
2.5 Quality of extemporaneously prepared medicines 
Medicines are subject to regulation to provide acceptable quality, safety and efficacy of the 
product. Medicines are registered and approved for intended usage by regulatory bodies in 
different countries, guided by the Good Manufacturing Practices (GMP) guidelines. “These 
guidelines are designed to facilitate compliance by the regulated industry and to enhance 
consistency in the application of the regulatory requirements” (Canadian GMP guidelines, 
2009). Important players in the current environment on ensuring the safety, quality and 
efficacy of medicines are the regulatory bodies in different countries. The quality of 
compounded preparations is ensured by adherence to the standards outlined in the 




The World Health Organization has recommended a special role for pharmacists in the 
quality assurance and safe and effective administration of drugs. This practice by 
pharmacists is governed by the South African Guidelines for Good Manufacturing Practice 
(GMP) which specifies the minimum standards required to maintain the quality of the 
product and ensure the safety of patients. These guidelines include a number of standards 
that should be nationally and internationally compliant and comparable with those of the 
agencies like the World Health Organization (WHO) and the Food and Drug Association 
(FDA).  
Compounding practices, which individually influence the quality of medicines, are based on 
the standards in the Pharmaceutical Inspection Co-operation Scheme (PICS) guidelines, the 
European Pharmacopoeia which is used as an official regulation for the extemporaneous 
preparations and the South African regulatory body, the MCC. The standards are discussed 
below using the following variables:  
(a) Good documentation “constitutes an essential part of the quality assurance system. 
Clearly written documentation prevents errors from spoken communication and permits 
tracing of information for drug reaction for an example. Specifications, compounding 
formulae and instructions, procedures, and records must be free from errors and available in 
writing. Clear Standard Operating Procedures (SOPs) should be in place for major items of 
compounding and equipment. The documents should be legible ” (USP, 2014). 
(b) Premises and equipment must be located, designed, constructed, adapted and 
maintained to suit the operations to be carried out. Their layout and design must aim to 
minimise the risk of errors and permit effective cleaning and maintenance in order to avoid 
cross-contamination, buildup of dust or dirt and, in general, any adverse effect on the quality 
of products” (USP, 2014). 
(c)  Personnel – “The establishment and maintenance of a satisfactory system of quality 
assurance and the correct manufacture of medicinal products relies upon people. For this 
reason there must be sufficient qualified personnel to carry out all the tasks which are the 
responsibility of the manufacturer. Individual responsibilities should be clearly understood 
by the individuals and recorded. All personnel should be aware of the principles of GMP 
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that affect them and receive initial and continuing training, including hygiene instructions 
relevant to their needs” (USP, 2014). 
The WHO is the directing and coordinating authority for health within the United Nations 
system (Oceania Health Consulting, 2005). Its responsibility is to provide for leadership on 
global health matters, shaping the health research matters, setting the health norms and 
standards, providing technical support to countries and monitoring and assessing health 
trends, while the International Conference Harmonization (ICH) is seen as the element that 
facilitates the commercial relationship between the Southern African Development 
Community (SADC) countries, and to ensure that the entire region benefits from the rapid 
availability of medicines which are safe, efficacious and of quality. The ICH includes the 
United States of America, Japan and the European countries (Oceania Health Consulting, 
2005). The well regulated countries are Canada, Australia and the Nordic region.  
According to the European Agency for the Evaluation of Medicinal Products (EMEA, 2002) 
meeting, there are no common European standards or guidance for extemporaneous 
preparations in contrast to those manufactured medicines that have to comply with GMP 
requirements. There is, therefore, a possibility of having different standards and it may be 
that not all of them would yield a safe, good quality and efficacious product.  
Extemporaneous compounding is guided by GMP guidelines, including standards for the 
equipment utilized, the staff involved in the process, the storage of raw materials and the 
finished product and specifications for the premises. 
2.6 Standard of  pharmacy personnel  skills and practice in extemporaneous 
compounding  
Although extemporaneous compounding has inevitably remained the domain of the 
pharmacist, some evidence reveals that other professionals, especially medical specialists 
such as naturopaths and herbalists (Feldschuh, 2008), also do it, even when the modern 
scientific technologies have produced new chemical entities. Allen (2012) insist that 
pharmacists possess knowledge and skills that are unique and not duplicated by any other 
profession.  
The goal of this study was to look at the level of competency of the compounding staff in 
the compounding practice in an attempt to provide access to safe and quality 
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extemporaneously prepared preparations to specific groups of patients. As such, pharmacists  
are often faced with the prospect of preparing new prescribed dosage forms not 
commercially available and tailored to the patient’s therapeutic needs. Again, pharmacists in 
the hospital settings are responsible for assuring the quality of all compounded preparations, 
largely due to their professional obligation and training enabling them to perform 
extemporaneous compounding (Nunn, 2003). Compounding skill is a required competency 
for practice for registered pharmacists in many countries (Kairuz et al., 2007b).   
Whether or not South African hospital pharmacies have adequate equipment and storage 
facilities for the raw materials used for compounding extemporaneous products is a topic for 
another study. What is very clear though is that documentation of activities involving this 
practice need to be kept and updated throughout the process (Schultz, 2007). The principle 
of good documentation is that it is an essential part of the quality assurance system. Clearly 
written documentation prevents errors from spoken communication and permits tracing of 
batch history. Specifications, manufacturing formulae and instructions, procedures and 
records must be free from errors and available in writing. The legibility of documents is of 
great importance (Steinborn, 2004). Hence, Pharmacy Compounding was issued to establish 
guidelines for personnel and training, product classification and storage, beyond-use dating, 
equipment storage and maintenance and environmental control for quality (USP, 2014). 
These guidelines are in accordance with the 2014 USP Chapter 795, which aims to assure 
that compounding pharmacies use methods of quality assurance for all compounded 
products produced. The importance of these quality assurance methods is to help maintain 
the quality of the product at every stage of compounding to the point of dispensing, which 
again minimises the chances of adverse medicine events. This is so that the products 
maintain quality after leaving the pharmacy and so that adverse medicine events are 
prevented (Flores-Perez et al., 2008). 
According to the guidelines of the 2014 USP Chapter 795, all pharmacists are to comply 
with the record keeping requirements for their individual states.  Compounding documents 
are kept as standard guides of information to allow the next compounder to reproduce the 
same prescribed preparation. The compounding record lists the excipients and the person 
responsible for the compounding activity and the formulation record serves as the consistent 
source document for preparing the preparation. The formulation record lists the name, 
strength and dosage form of the preparation. It further includes the preparation ingredients 
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with their quantities, the equipment used and the method for mixing. The expiry date of the 
preparation is also included. These records’ retention period is the same as that required for 
any prescription, which is normally three years. According to Kairuz et al. (2007b), “the 
skill to compound non-sterile products is one of the seven competencies required of entry-
level pharmacists for registration with the New Zealand Pharmacy Council”. The need for 
extemporaneous compounding skills has been questioned in other countries, as it is argued 
that the skill is not often required in modern pharmacy settings (Kairuz et al., 2007a). 
Compounding risks can therefore be minimized through pharmacists’ skills for producing 
quality preparations, and by training with knowledge on quality assurance procedures. 
Possession of a qualification as a pharmacist or pharmacist’s assistant does not confer 
ability to carry out all functions. The level of the compounding skills and expertise, together 
with compliance to quality assurance procedures possessed by the pharmacists, were studied 
in Texas by Treadway et al. (2007) and the findings were that pharmacists did not receive 
training. However, policies and procedures on extemporaneous compounding were adhered 
to. The sources for compounding formulation were from published literature and no stability 
testing were done on the finished medicine produced. 
In the US, the pharmacy compounding law which is part of the Food and Drug 
Administration (FDA) Medicines Act of 1968 and Modernization Act of 1997 respectively 
define the limits of legitimate compounding. These guidelines specify minimum standards 
required to maintain the quality and to ensure the safety of patients. According to a report by 
Oceania Health Consulting  (2005), Australia has standards and guidelines that could ensure 
the quality of compounded preparations meeting very basic requirements, but the 
application of those standards seem to be a “hit-and-miss process” to compounding 
pharmacies, with no certainty from a national perspective. Standardized USP guidelines and 
the external enforcement of those guidelines by regulatory bodies such as the Joint 
Commission on Accreditation of Healthcare Organization (JCAHO) have the potential to be 
a significant step forward in further improvement of pharmacy compounding practices 
(Oceania Health Consulting, 2005). In this review of the need for further regulation of 
compounded preparations, the consultants indicated the lack of enthusiasm in setting 
compounded preparations quantity limits. The other reason is that compounded preparations 
are required to be produced to an appropriate standard, and quantity cut-off does not ensure 
that quality. Large scale compounding is done in anticipation of the need for the dosage 
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form. Batch production, where a medicine is compounded for one patient specifically, is a 
concern to the Therapeutic Goods Administration  as it has increased in other areas.  
However, it is still important that those who are compounding locally do so with compliance 
to GMP requirements in mind. The legislation in most countries, including Europe, 
Australia and the United States, allows this practice (Giam and McLachlan, 2008). In all 
these countries the GMP needs to be adhered to for all compounded products as they are not 
regulated as compared to the commercially available products. This is done so as to ensure 
that the product compounded is safe, of good quality and, once in use, efficacious. 
2.7 Global studies on extemporaneous compounding 
The studies done globally that have been reported from various studies are summarised and 
presented below in Table 2.2: 
Table 2.2: Global compounding studies 
Aspects of extemporaneous 
compounding studied 









Frequency Hospital Emegency 
Care 
Arizona  Phan et al., 
2010 
Frequency 
(drug consumption patterns) 
Hospital Mexico Florez-Perez, 
2008 
Frequency Hospital  Malysia  Lee et al., 
2012 
Extent Hospital pharmacy New Zealand Kairuz et al., 
2007a 
Education 
(practices of pharmacies) 
Institutional and 
hospital pharmacies 







Education (methods of 
extemporaneous preparation) 
Hospital pharmacy United Kingdom Brion et al., 
2003 
Formulation optimization Hospital and 
community pharmacy 
Australia Glass and 
Haywood, 
2006 








Table 2.2 indicates that studies encompassing frequency, extent, compounding education, 
development of regulatory policies and formulation optimizations related to 
extemporaneous compounding have been undertaken in other countries. It can be clearly 
seen (Table 2.2) that no such published study to date has been reported within South Africa 
on this subject. This is specifically needed within the South African setting due to the 
complex health challenges within the country and the clear existence of disease conditions 
and group of patients requiring extemporaneous compounded preparations. 
The main findings from some of the studies above are discussed hereunder: 
2.7.1 Mexico 
Flores-Perez et al. (2008) surveyed Mexico to determine the pattern of medicine 
consumption at the National Institute of Pediatrics from 2001 to 2006. They also developed 
a list of medications for which there is no adequate pediatric formulation.  It was found that 
furosemide, phenobarbital, omeprazole, midazolam, prednisone and captopril were the most 
frequently prescribed medicine for which no paediatric formulation is available. This could 
imply that this reflects increased cases of metabolic syndrome in children necessitating the 
use of these medicines which were normally only used predominantly in adults. 
2.7.2 United Kingdom 
Each year 26% of children in the UK receive an off-label prescription from their general 
practitioner, signaling a strong prevalence of the practice (Stewart et al., 2007). This study 




According to Feldschuh (2008), extemporaneous compounding is still taught as part of the 
pharmacy curriculum although it is practiced to a lesser extent by local pharmacists. In his 
review in 2008, of all products with approved paediatric indications, close to 24% were not 
available in a form suitable for administration for children. This report also indicated that 
metronidazole vaginal gel is an example of a product available overseas which is 
compounded by a pharmacist if required by an Australian patient (Feldschuh, 2008). 
2.7.4 New Zealand   
In the survey carried out by Kairuz et al. (2007a) on extemporaneous compounding in 
NewZealand hospitals it was revealed that extemporaneous preparation for oral use involved 
the reformulation of 74 drugs out of 2015 products over a period of seven months in seven 
hospitals. Medicines requiring extemporaneous preparation included reformulation of 
capsules (Ursodeoxycholic acid and Omeprazole), including Propranolol and Folic acid 
tablets. These solid dosage forms are crushed and suspended and made into a liquid oral 
dosage form. Midazolam, a bitter tasting medicine, is an example of a tablet crushed and 
suspended in a liquid. Other dosage forms in the form of powders such as Phenobarbitone 
sodium and Magnesium hydroxide were extemporaneously prepared. The off-label use of 
medicines was also reported. There were ten most frequently compounded medicines within 
the seven months of study in the seven hospitals out of the eleven which responded.  These 
were Thyroxine, Metoprolol, Sucralfate, Hydrochlorothiazide, Amiodarone, Soltalol, 
Diazoxide, Ursodeoxycholic acid, Omeprazole and Propranolol. Furthermore, Omeprazole 
suspension was found to be compounded at all hospitals, while Ursodeoxycholic acid 
suspension was compounded for children at only one hospital which had a paediatric unit. 
Some of the medicines which were extemporaneously compounded were Allopurinol, 
Baclofen, Clobazam, Clonidine, Diazepam, Domperidone, Pilocarpine Nitrate and 
Terbinafine.  
2.7.5 United States of America 
Allen (2001) conducted a study in Oklahama city where it was estimated that 
dermatological skin disorders occurred in 5% of the population, and extemporaneous 
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compounding could be beneficial for other routes of administration and different dosage 
forms other than oral could be used to accommodate the prescriber’s specific needs. 
2.8 Conclusion 
Most medicines which are manufactured by pharmaceutical industries are authorised for 
adult administration. There are, however, situations that dictate the manipulation or 
extemporaneous compounding of medicines for provision of healthcare to paediatrics, 
geriatrics and adults with swallowing difficulty to administer such medicines in a solid 
dosage form. Compounded medicines are prepared by a pharmacist who received teaching 
on compounding skills to prepare and to assure safety and quality of the final medicines. 
The above literature review emphasises the important role that extemporaneous 
compounded preparations play in meeting specific needs of patients. It also shows that this 
aspect of health care is being studied in several countries whilst none has been officially 
reported for South Africa. The review emphasises the global lack of quality testing on these 
preparations elevating the risks of their use in patients. There is a need for compounded 
medicines to be regulated with standardised methods of preparation. The compounding risks  
can be minimised through pharmacists’ skills, training and knowledge on quality assurance 
procedures. Extemporaneous compounding, therefore, plays a critical role in optimising 
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3.2 Submitted manuscript 
Investigating extemporaneous compounding practices in the Polokwane tertiary 
hospital pharmacy in South Africa – a pilot study 
Euphenia Mathebule Masupye1,2, Fatima Suleman2, Thirumala Govender2 
1Department of Pharmacy, University of Limpopo, Private Bag X1106, Sovenga, 0727,  
South Africa. 
2Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Private Bag X54001, 
Durban, 4000, South Africa. 
Abstract 
Medicine availability is an important aspect of providing good quality health care. Some 
medicines are available in doses that are not suitable for a specific population group and 
therefore manipulation of the existing medication is undertaken in order to obtain the 
required concentration of that medication. Studies on the practices, frequency and extent of 
extemporaneous compounding have been undertaken in other countries such as New 
Zealand, Australia, United Kingdom, United States of America, Netherlands and Mexico. 
No data currently exists for South Africa. Therefore, the aim of this pilot study was to 
explore the extemporaneous compounding practices in a South African public sector setting. 
A quantitative research approach applying a cross-sectional research design was used in this 
study to determine the extemporaneous compounding practices in a tertiary hospital 
pharmacy. Twenty-five pharmacists responded to a questionnaire on their knowledge and 
practices. Data was collected from 691 batch records and prescriptions dating from the April 
2008 to March 2009 to determine the frequency and extent of extemporaneous 
compounding. Data was analyzed using the Statistics Package for Social Sciences (SPSS 
version 20.0; 2011). Most (96%) of the pharmacy personnel indicated having received 
compounding training skills through supervision by experienced pharmacists. 72% 
explained that they compounded medication due to the unavailability of the prescribed 
drugs. Most (60%) of the respondents confirmed that the expiry date is personally 
developed. This study identified the need for more research into this practice and the use of 
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evidence from literature-based information for aspects like stability testing to assure the 
medicines’ quality and compounding practice.  
Keywords: Extemporaneous, compounding, quality, quality assurance,  
 
Introduction  
The global and chronic lack of licensed medicines and appropriate dosage forms and 
strength for specific groups of patients is widespread and has sparked the initiation of 
extemporaneous compounding practice worldwide (Brion et al., 2003; Giam et al., 2012). 
The need for extemporaneous compounding is further observed in the case of a rare disease 
condition that requires a tailor-made therapy for a specific patient (Salgado et al., 2005; 
Spark, 2014). Other reasons for extemporaneous compounding are sensitivity/allergy to 
certain excipients and preservatives, different dose availability or different routes of 
administration required, or compliance problems related to the use of some medications, for 
example palatability of the formulation/medicine (Feldschuh, 2008; Spark, 2014). The dose 
or the dosage form registered as such might not be suitable or appropriate for paediatrics, 
geriatrics or those adults who are unable to swallow solid dosage forms and those for whom 
medication is administered in a liquid form through naso-gastric tubes due to poor 
swallowing reflexes necessitating extemporaneous compounding (Standing and Tuleu, 
2005; Kairuz et al., 2007a; Giam et al., 2012). All these problems, coupled with pervasive 
lack of commercially available suitable drugs, have thus resulted in the need to make use of 
extemporaneous preparations in most hospital pharmacies.  
Giam and McLachlan (2008) defined extemporaneous compounding as the extemporaneous 
preparation, mixing, packaging or labeling of a drug as the result of a practitioner’s 
prescription drug in order to meet an individual patient’s need. They may be formulated 
from existing dosage forms (Brion et al., 2003; Haywood and Glass, 2007; Spark, 2014) 
which entails crushing commercially available tablets and capsules contents into a suitable 
liquid dosage form with the aim of providing accessible essential medications to, amongst 
others,  patients who are unable to swallow solid dosage forms (Nahata and Allen, 2008). 
On the other hand, in the United States, the Food and Drug Administration (FDA) regards 
traditional pharmacy compounding as the extemporaneous combining, mixing, or altering of 
ingredients by a pharmacist in response to a physician’s prescription to create a medication 
tailored to the specialized medical needs of an individual patient.  Traditional compounding 
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typically occurs when a regulatory body-approved drug is unavailable or a licensed health 
care provider decides that an approved drug is not available in the appropriate dosage form 
for his or her patient’s medical needs. Extemporaneous compounding may again occur in 
the case of the manipulation of the product’s strength suitable for adult use, where the 
prescriber needs a lesser strength for an infant (Kairuz et al., 2007b). 
Improperly compounded, adulterated drugs have the potential to cause significant harm to 
patients (Food and Drug Administration, 2006). The global lack of documented and 
standardized formulae (Sellers et al., 2012) poses a high risk to patients as there may be 
variation in manufacturing methods used. Furthermore, the excipients used may differ 
greatly and their effect on the stability and quality of the compounded product cannot be 
guaranteed. These studies emphasize that without strict observance of good manufacturing 
practice guidelines it is possible to have miscalculations of the respective quantities of each 
ingredient and this could be problematic especially where the system and processes are not 
tightly regulated.   
A number of problems have been reported in recent years due to a lack of quality assurance 
processes. In the United States a 2012 meningitis outbreak was tied to the now-shut New 
England Compounding Center in Framingham that killed at least 64 people and sickened 
750 more. Inspections subsequently found unsanitary conditions at the company's facility 
(Shaughnessy, 2012). Between March and April 2013, the FDA requested a number of 
voluntary nationwide recalls for compounded products due to a lack of sterility assurance 
(Food and Drug Administration, 2014). In South Africa, in the last decade, problems were 
also detected with the mixing of traditional medicines and conventional medicines that had 
serious adverse events (Snyman et al., 2005).  
While most countries such as New Zealand (Kairuz et al., 2007a), Australia (Feldschuh, 
2008), United Kingdom (Steward et al., 2007), United States of America (Treadway et al., 
2007), Netherlands (Giam and McLachlan, 2008) and Mexico (Flores-Perez et al., 2008) 
have undertaken studies to determine the skills of staff compounding medicines, as well as 
the frequency and extent of extemporaneous compounding, no data exists for South Africa.  
Such studies are essential for improving the care of patients, especially because of the 
unique and complex health challenges in the country including the HIV/AIDS crisis and the 
compounding that takes place for paediatric preparations.  
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The purpose of this pilot study was to explore the extemporaneous compounding practices 
in South African public sector  setting in order to evaluate the standards of compounding.  
Materials and Methods 
This was a cross sectional descriptive pilot study, that was conducted in the Polokwane 
Municipality, which is in the Capricorn District of Limpopo Province, South Africa, and has 
44% of the district population. The Province is situated in the north east of South Africa, 
covering a geographical area of 124 kilometersand is made up of five districts, namely: 
Vhembe, Mopani, Capricorn, Sekhukhuni and Waterberg. The Capricorn District has five 
municipalities (Statistics South Africa, 2007) in total. According to the Limpopo 
Department of Health and Social Development (2008) the Department operates and 
manages 49 hospitals with a population of 5,514 million and approximately 500 health care 
centres and clinics. These centres have approximately 11 400 beds, including 560 clinic 
beds. Of the 49 hospitals, six are regional and three specialized hospitals. Of the remaining 
forty, 38 are district hospitals and one Polokwane/Mankweng hospital complex with a 
combination of two hospitals - Pietersburg Campus and Mankweng Campus and a tertiary 
hospital with 470 beds. (Limpopo Department of Health and Social Development, 2008). 
The two hospitals forming the Polokwane/Mankweng hospital complex serves 47 other 
hospitals in the entire province. 
A purposive selection was conducted to select the tertiary hospital in the province as the site 
of study. This was specifically due to the health professional specialization in this study 
area. A tertiary hospital is a referral hospital with a medical specialty mix at its disposal. It 
provides specialist level services and receives referrals from six regional hospitals, where a 
regional hospital provides health services in the fields of internal medicine, paediatrics, 
obstetrics, gynecology and general surgery on a 24-hour basis.  
Pharmacists in the hospital settings are responsible for assuring the quality of all 
compounded preparations according to Nunn (2003). This is largely due to their 
professional obligation and training enabling them to perform extemporaneous 
compounding and also being cautious in making sure that all formulations are followed to 
the letter in order to maintain acceptable compounding standards. Compounding skill is a 
required competency for practice for registered pharmacists in many countries, more 
especially in New Zealand (Kairuz et al., 2007a). 
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Thus, a purposeful sampling was conducted to select the pharmacists. A self-administered 
close-ended and open-ended questionnaire was designed to collect information from the 
pharmacists and the pharmacy managers for characterization of the compounding practice 
processes for quality assurance on seven items, namely: a) the pharmacist’s demography, b) 
the education level, c) class of personnel, d) training methods, e) procedures and policies for 
extemporaneous compounding, f) how expiry dates are determined and g) the most common 
reasons for undertaking extemporaneous compounding. The questionnaire was adopted from 
a previously used one and verified by Treadway et al. (2007) and then modified in this study 
to include additional variables. The questionnaire was designed to record the information 
required and piloted in a large hospital pharmacy department prior to undertaking the 
survey. It was completed on the pharmacists’ spare time and final collection was after six 
months. The participants’ identification was coded for anonymity. The pharmacists willing 
to participate in the study signed the consent form and completed the questionnaire after 
information about the study was explained by the researcher. The study was conducted 
between 1stJanuary 2008 and 31st December 2009. 
In order to assess the frequency and the extent of extemporaneous compounding in the 
hospital pharmacies of the Polokwane Municipality, retrospective data collected on a 
modified data sheet designed by Kairuz et al. (2007a) was initially used. A data collection 
sheet was designed to record the information required for this aspect of the study and piloted 
in a large hospital pharmacy department in the same district prior to undertaking the survey. 
All the batch records from April 2008 to 31st March 2009 were purposefully sampled. The 
data collection sheet was amended to provide the following information: the name of the 
compounded drug, strength, quantity produced, route of administration, dosage form, 
storage conditions, expiry date, date of preparation, and disease condition.  
Retrospective data was collected on site using the data collection sheet which was 
formulated to determine the number of extemporaneously compounded preparations out of 
the total number of prescriptions for the period of the study, April 2008 to March 2009. This 
measured the extent of extemporaneous compounding. A purposeful sampling was 
conducted to select the prescriptions. 
All extemporaneously compounded preparations in the data collection sheet were coded on 
a coding sheet and captured on Microsoft Excel®. All variables for assessing the frequency 
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and the extent of extemporaneous compounding were coded and captured as well on 
Microsoft Excel®. (Version 12, released in 2007). The scale question was coded from “1” to 
“4” with “1” representing “Never” and “4” representing “Always”. “Yes” and “No” were 
coded such that “1” represented “Yes” and “2” represented “No”. All questionnaires were 
coded and captured on Microsoft Excel®. The analysis consisted of descriptive and 
analytical components.  This was done using the Statistics Package for Social Sciences 
(SPSS Version 20, 2011).  
Ethical Considerations 
Written permission to conduct the study was sought from and granted by the Research 
Ethics Committees (HSS/0984/2009) of the University of KwaZulu-Natal, The Limpopo 
Provincial Department of Health and Social Development  and the hospital- Chief Executive 
Officers (CEO). 
Results 
Expertise of Personnel 
Fifty-nine questionnaires were distributed to tertiary hospital pharmacy personnel. Only 25 
were returned, resulting in a 42.37% response rate. The low response rate was due to non-
availability of respondents to participate because they verbally mentioned large daily 
workload as a reason. 
The demographic profile of the sample depicted in Table 1 indicated that the majority of the 
pharmacists were female (56%) while 44% were male. Pharmacy personnel in the age  
range of 20 and 30 years made up 36% of the sample, while those in the age range 31 to 40 
comprised 32% of the sample.  
There was an equal distribution of senior pharmacists (20%) and the registered pharmacy 
assistants (20%) in the personnel category.  With regard to the pharmacists’ level of 





Table 1 Dermographic profile as percentages of the total sample  













Age (years) 20–30  
31-40  
41-50  













Registered pharmacy assistant 
Community pharmacist 


















Bachelor of Pharmacy 









Almost all of the pharmacists (96%) indicated that they have received compounding training 
skills through supervision (80%),   compared to 64% who stated that they received their 
experience via personal experience. Different findings of the training on compounding skills 
(69%) were reported in Texas by Treadway et al. (2007). Treadway and colleagues cited a 
study by Morris et al. (2002) with a training rate of 96% for pharmacists and 89% for 
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technicians. Training content (as outlined in Table 2) included information sourcing (56%), 
use of reference materials (68%), use of equipment like weighing scales, compounding tile 
for creams and ointments (96%), labelling according to recommended guidelines (92%), 
compounding record keeping (92%) and formulation record keeping (80%). A key finding 
in this study was the limited training in aseptic technique (12 %), which if not followed 
properly could result in contamination of compounded products with serious effects on 
patients. 
Table 2  Compounding skills training areas 
Which training areas are covered in 
your training? 
Agree  Disagree  
Frequency  % Frequency  % 
Sourcing formulation 14 56 10 40 
Use of references 17 68 8 32 
Use of equipment, mortar and 
pestle, balances, etc 
24 96 1 4 
Labelling 23 92 2 8 
Compounding record keeping 23 92 2 8 
Formulation record keeping 20 80 5 20 
Aseptic technique 3 12 22 88 
Other 6 24 19 76 
 
The pharmacy personnel were asked how often the following listed records were included in 
the documentation of their pharmacy. Their responses are shown in Table 3. 
Table 3  Documentation of compounding in the hospital 
 
How often are the following listed records 
included in the documentation of this 
pharmacy? 
Never Sometimes Often Always 
Manufacturing batch records 4% 8% 8% 80% 
Compounding formulae and direction for 
compounding 
8% 4% 16% 72% 
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A log of all compounded items 4% 8% 20% 64% 
Balance - maintenance log books 64% 4% 12% 16% 
Standard Operating  Procedures 12% 8% 24% 52% 
 
The study found 92% availability of compounding policies and procedures to ensure 
consistency in the production of the same product for different batches, compared to the 
findings by Treadway et al. (2007) of 71% in pharmacies in Texas. In the Treadway et al. 
(2007) study, two thirds of the pharmacies claimed to have no policies and procedures and 
did not provide staff training. Further, in this study (Table 3), there was no proof of records 
being kept on regular calibration of electronic weighing balances (76%) and maintenance 
(72%) despite the fact that documentation for compounding comprising of a manufacturing 
batch record are mostly kept (at 80%), as well as compounding formula and procedures 
(72%). A logbook of all compounded items was not kept in most instances (64%). The study 
further revealed that maintenance of the weighing balances was not carried out in most cases 
(64%). 
Table 4 Resources used for obtaining formulations in hospital pharmacy 















Missing  12%         3 
 
Table 4 shows resources which the pharmacy personnel use for obtaining compounding 
formulations. There are conflicting results regarding self-reports on the source of 
compounding formulations from published literature (40%) in Table 4 versus self-reports on 
in-house formulations which are personally developed (28%). The verbal report from the 
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compounding pharmacists was that all the formulations used for compounding were self-
derived. The hospital has compiled and used a formulation document containing the 
formulation of a product, method of preparation, quantities prepared, storage temperature, 
date of compounding and shelf-life. The results are in contradiction to those  by Treadway et 
al. (2007) as in that study 82% used published literature and 40% were personally developed 
despite the emergence of more established sources for compounding formulations. In terms 
of determining an expiry date, the results shown in Table 5 revealed that 60% of the 
respondents confirmed that the expiry date was personally developed. There was 
inconsistency in documenting these dates. No stability and quality control tests were carried 
out to assess physical, chemical and microbiological changes or for the suitability of the 
formulation in terms of the active material content and shelf-life. 
 
Table 5 Establishing expiry dates 
 N=19(6 missing 24%)  






In-house stability testing 
External stability testing 
Recommendations from other hospital pharmacies 
Recommendations from other pharmacies 

















The pharmacy personnel were asked about the challenges they encounter in the preparation 
of compounded products. They strongly agreed (96%) that formulations were available in 
the pharmacy and that calculations were not (84%) a challenge. However, Standard 
Operating Procedures were not revised (72%). The main reasons for compounding were 
unavailability of a prescribed drug (72%), unsuitable dosage form (44%) and unsuitable 
route of administration (32%). 
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In Treadway et al.’s (2007) study on practices of pharmacies that compound 
extemporaneous formulations, unsuitable dosage form as a reason for compounding was 
found to be the lowest (16%) and cost at (50%) was the main reason for compounding.  
While extemporaneous compounding practice processes are for improving compounding 
efficiency and effectiveness of compounded medicines, and to generate knowledge to 
compounders in order to help raise the standards of compounding and prevent the risk of 
patient harm, it was necessary to investigate what dosage forms and products were being 
compounded in Polokwane hospital pharmacies. This study, therefore, examined these 
aspects from batch records. 
The nature of products being compounded 
The results for the products being compounded were assessed by reviewing 691 batch 
records. There was an average of 27.64% preparations compounded per month. Solutions 
accounted for 43.9 % of the most frequently compounded dosage forms. This study revealed 
that dermatological preparations, that is, creams and ointments totalling 33.0% and 13.60% 
respectively (46.60%) are mostly compounded at the hospital. In a study by Buurma et al. 
(2003) who evaluated the frequency of compounding in the Dutch community pharmacies, 
the findings were that it consisted largely of dermatological preparations and dermatological 
dosage forms. A contrary result was found by Kairuz et al. (2007a) in the New Zealand 
hospital sample survey in determining the extent and nature of compounding, where oral 
suspensions were the most compounded dosage form with a reformulation of Omeprazole 
being the most frequently compounded drug.  
The most compounded product was Betamethasone (27.9%). The shelf-life given for 
extemporaneously compounded preparations was found to be range from six months at 
66.3%, three months at 14.5% to 12 months (9.8%). According to Brion et al. (2003) an 
unpublished UK survey showed that 54% of 112 pediatric extemporaneous formulations had 
inadequate data on shelf-life. This is due to lack of  extensive research that will need to be 
undertaken to establish the suitability of the formulation on its stability. 
A considerable number (98.30%) of extemporaneously compounded preparations were 
reported to be stored below 25℃.  Only a small number (1.70%) were refrigerated at 2℃ -
8℃.  The refrigerated solutions were found to be the oral solutions containing minerals for 
supplementation. The other dosage forms and other oral and non-oral solutions were stored 
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below 25℃. Most of the preparations were extemporaneously prepared from commercially 
available drugs where the prescriber needed a lesser strength for a specific patient condition, 
irrespective of the patient’s age.  
Discussion 
Compounding errors are an emerging and serious problem. Pharmacists hold a unique 
position as health professionals who are formally trained in compounding medications and 
are licensed to dispense them. 
This research attempted to gain an understanding of compounding practices in the tertiary 
hospital pharmacies in the Polokwane Municipality as confirmed by the study by Treadway 
et al. (2007) that confirmed that there are serious questions about the quality of compounded 
preparations. Most of the pharmacists in this study received their training as part of the 
undergraduate curriculum. A study by Eley and Birnie. (2006) indicates that pharmacy 
students do not adequately retain compounding knowledge and skills, and that pharmacy 
students’ level of competency and retention of knowledge with respect to compounding 
capsules is not adequately retained after a 12-month hiatus. There is thus a need to look at 
competency assessments for compounding pharmacists as well as continuous professional 
development in this area. 
This study indicated that extemporaneous compounding is not subjected to a quality control 
procedure beyond calculations, ingredients checking and visual inspection which is in 
agreement with the findings from Donnelly et al. (2008). This is in contrast to the quality 
control operations pertaining to proprietary products manufactured by the pharmaceutical 
industry, where GMP standards are followed (Donnelly et al., 2008).  
There have been attempts in the past decade, according to Treadway et al. (2007), to raise 
the standard of all compounding practices through the efforts of the United States 
Pharmacopeia (USP) and the American Society of Health-System Pharmacists (ASHP) 
through ASHP guidelines on Quality Assurance for Pharmacy–Prepared Sterile Products in 
2000. More recently, the USP has implemented further procedures and requirements on 
compounding non-sterile and sterile preparations in an attempt to help raise the standards of 
compounding and prevent the risk of patient harm. This is largely absent in South Africa. 
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Our study indicated a frequency of compounding at this hospital as being between 40%-
50%. In the United States it has been estimated that approximately 1% of prescriptions are 
compounded, representing nearly 30 million prescriptions annually. A similar estimate has 
been made for compounded prescriptions produced in Australia (Giam et al., 2012). 
Our study revealed that pharmacy compounding consists mostly of dermatological products 
and dermatological dosage forms.  This data confirms results from Buurma et al. (2003). 
Another study in New Zealand  hospitals by Kairuz et al. (2007a) revealed suspensions to be 
the mostly compounded preparations with creams, ointments and non-oral solutions being 
the most commonly prepared. The shelf-life given for extemporaneously compounded 
preparations was found to be three months, six months and 12 months. However there are 
some products which should be used within 24 hours of preparation.  According to Brion et 
al. (2003) an unpublished UK survey showed that 54% of 112 pediatric extemporaneous 
formulations had inadequate data on shelf-life. This suggests that extensive research needs 
to be undertaken to establish the suitability of the formulation on its stability. Lack of time, 
expertise and facilities in hospital pharmacies, among other factors, limit the undertaking of 
such research. 
Conclusions 
There is a need for professional organizations to play a role in extemporaneous 
compounding as a source of compounding formulations and quality assurance guidelines. 
This could be a way to increase the quality of available formulas by using a central source 
of information as well as guidelines for expiry date determination and equipment calibration 
among other quality assurance processes. There is a need for more research on the 
compounding practices in both public and private sector facilities in South Africa. 
Further research on internationally harmonized guidelines for extemporaneous 
compounding to supplement formulation development needs should be established, as in 
countries like the USA where the ASHP has developed guidelines on standards of 
compounding to prevent the risk of patient harm. In South Africa, like all other countries, 
there is a need to train pharmacists on compounding skills and to regulate and standardize 
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CHAPTER FOUR:  CONCLUSIONS AND RECOMMENDATIONS 
4.1 Introduction 
In this chapter conclusions from the findings of the study are drawn and limitations of the 
study and recommendations for future research and strategies to improve or maintain the 
compounding practice are proposed. The aim of this pilot study was to explore 
extemporaneous compounding practices in a South African public sector setting in order to 
help evaluate the standards of compounding. The findings are discussed in accordance to the 
objectives of the study.  
4.2 Conclusions 
4.2.2.1 To assess the skills set and capacity of the staff compounding medicines 
in the tertiary hospital pharmacy in the Polokwane Municipality.  
 
In this pilot study, it was observed that the majority of the pharmacists were receiving 
compounding skills training through supervision by experienced pharmacists on the use of 
equipment like the mortar and pestle and weighing of balances, yet the maintenance of the 
weighing balances was not carried out in most instances. Also, there were no stability and 
quality control tests carried out to assess physical, chemical and microbiological changes or 
for the suitability of the formulation in terms of the active material content and shelf-life. 
Expiry dates were personally developed. Another finding was the limited training in aseptic 
technique. There was also no proof of records kept on regular calibration and maintenance 
of electronic weighing balances, despite the fact that documentation for compounding in 
terms of manufacturing batch record were largely kept.  A logbook of all compounded items 
was also not kept.  
  
4.2.2.2 To identify the most common dosage form and product being compounded in 
the tertiary hospital pharmacy in the Polokwane Municipality. 
This pilot study revealed that small scale extemporaneous compounding is occuring in a 
tertiary hospital pharmacy in the Polokwane Municipality. Dermatological creams are the 
most frequently compounded category of medicines currently. A considerable number of 
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solutions, both oral and those used for disinfection or used as an antiseptic, were also 
compounded. 
4.3 Limitations of the study 
The aim of this pilot study was to determine the extemporaneous compounding practice in a 
South African public sector hospital setting. The methods employed to generate the findings 
in this study were in line with those employed in other studies. However, certain limitations 
as described below should be noted: 
 
• The results from only one tertiary hospital does not constitute a large enough sample to 
draw firm conclusions about the practice in the entire province and South Africa. 
 
• The patients’ information regarding age and disease condition were not available from 
the file and could not be captured. The availability of such information on 
documentation of extemporaneous compounding improves the availability of 
information on medicines for different patients’ needs and for future modification of 
existing dosage forms by researchers to ensure maximal therapeutic responses. 
4.4 Recommendations for future work 
The following recommendations may be considered for further extemporaneous 
compounding studies: 
 
RESEARCH: This pilot study gives some indications regarding the level of competence of 
the extemporaneous compounding staff as well as extemporaneous compounding practices 
at the tertiary hospital pharmacy in the Polokwane Municipality. The findings suggest that a 
wider in-depth research at a national level should be explored to determine the need for 
quality control in compounding practices and competence of staff. Further research on a 
national level to determine the frequency and extent of the compounding practice in both 
public and private sector facilities in South Africa and Africa will be important. Further 
investigations into the formulae used when compounding is needed as most may not be from 




 GUIDELINES/POLICIES/REGULATIONS: The study has shown the lack of stability 
studies on the compounded medicines, which hints at the need to prepare guidelines on good 
pharmaceutical practice in hospital and community pharmacies in relation to 
extemporaneous preparation in order to use a uniform standard. It further suggests research 
on internationally harmonized guidelines for extemporaneous compounding to supplement 
formulation development, and for professional organizations to play a role in 
extemporaneous compounding as a source of compounding formulations.  
 
EDUCATION: The pharmacy undergraduate curriculum may need to be reviewed for 
relevance of content related to the compounding practice, which is suggested by the low 
aseptic t technique skill shown in this pilot study. 
 
4.5 General Conclusions 
 
Stability and quality control tests carried out to assess physical, chemical and 
microbiological changes for the suitability of the formulation in terms of the active material 
content and shelf-life are considered to be a needful necessity since there have been none 
carried out so far. The recommendations for further research on internationally harmonized 
guidelines for extemporaneous compounding to supplement formulation development as 
well  as the dire need to further train pharmacists on compounding skills (including the 
aseptic technique) and to regulate and standardize extemporaneous compounding so as to 
avoid usage of varying formulation methods are of utmost importance and therefore they 
need to be implemented. 
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ANNEXURE 5: Data collection tool for pharmacists 
 
PHARMACISTS INTERVIEW INSTRUMENT 
 
Name of hospital:  ________________________________________________ 
 
Code allocated to hospital:  _______________________________________ 
 
1. Demographic data 





1.2  Gender     
 
1.3 Race        
1. Black 1 
 
2. White 2 
 
3. Indian 3 
 
4. Coloured 4 
 
5. Chinese 5 
 





20 – 30 1 
31 – 40 2 
41 – 50 3 
51 – 60 4 



























2 Compounding skills 





1. Chief pharmacist 1 
2. Principal pharmacist 2 
3. Senior pharmacist 3 
4. Pharmacist  4 
5. Pharmacy intern 5 
6. Registered pharmacist  assistant 6 
7. Unregistered pharmacist  assistant 7 
8. Community service pharmacist 8 
9. Pharmacy assistant basic  
10. Pharmacy assistant learner basic  
1. Doctorate 1 
2. Masters 2 
3. Bpharm 3 
4. Diploma in Pharmacy 4 





2.2 Which training methods are used for pharmacy staff in your hospital for 
compounding? 
(Tick the appropriate method applicable) 
1. On the job via personal practice Yes 1 No 2 
2. Formal lecture Yes 1 No 2 
3. Video Yes 1 No 2 
4. Supervision by experience Yes 1 No 2 
5. Training by external service providers Yes 1 No 2 
 
6. Other (specify) 
 
 






1. Sourcing or retrieving formulation Yes 1 No 2 
2. Use of references Yes 1 No 2 
3. Use of equipment in compounding, e.g. electronic balances, 
mortar and pestle, ointment slabs, etc 
Yes 1 No 2 
4. Labelling Yes 1 No 2 
5. Record keeping: compounding record Yes 1 No 2 
6. Record keeping: formulation record Yes 1 No 2 
7. Tests conducted Yes 1 No 2 
8. Quality assurance processes on, e.g. aseptic technique Yes 1 No 2 




2.4 What compounding challenges do you encounter in your pharmacy? 
1. No formulations 1 
 
2. Calculations  2 
 
3.Standard Operating Procedures not revised 3 
4.Other (specify) 4 
 
 
3. Compounding procedures 
3.1 How often are the following listed records included in the documentation of this 
pharmacy? 
 
 Never  Sometimes  Often  Always 
 
1. Manufacturing batch records     
2. Compounding formulae and 
procedures 
    
3. A log of all compounded items     
4. Balance maintenance      
5. Standard Operating  Procedures     
 
 










1. Published literature(specify) 1 
 
2. Other hospitals 2 
3. Other pharmacies e.g. retail 3 
4. Personally developed/in-house formulations 4 
61 
 
4 Establishment of expiry dates 
4.1 How are expiry dates for compounded preparations established? 
      1.   In-house stability testing  
1 
2. Eternal contractor for stability testing 2 
3. Recommendations from other hospitals pharmacies 3 
4. Recommendations from pharmacies, e.g. retail 4 
5. Personally established generalized expiry dates for various dosage forms 5 




4.2 Are the following available in your pharmacy? 
 Yes  No  
1. Compounding policies and procedures  
 
  
2. Electronic balances 
 
  
3. Proof of record of regular calibration of balances  
 
  
4. Proof of record of regular maintenance of balances 
 
  















4.4  What are the reasons for compounding in your pharmacy? 
       1.    Allergy 1 
 
2. Prescription drug not available  
2 
3. Unsuitable dosage form  
3 
4. Unsuitable route  
4 
5. Cost   
5 
6. Taste   
6 























ANNEXURE 6: Data collection sheet for the compounded medicines 
     
  




DATA COLLECTION SHEET 
     





     
   
NAME OF HOSPITAL 
   
 
 
NAME OF HOSPITAL 
      
   
CODE ALLOCATED 




      
        
 
         Name of prep
aration & stre

















ms if any 
Class of P
atient         
                        
 
Geriatrics Neonates Infants Children Adults  
                        
 
  0-27 days 
28 days- 23 
months 2-11yrs   
1               1 1                 
2               2 2                 
3               3 3                 
4               4 4                 
5               5 5                 
6               6 6                 
7               7 7                 
8               8 8                 
9               9 9                 
10               10 10                 
11               11 11                 
12               12 12                 
13               13 13                 
14               14 14                 
15               15 15                 
16               16 16                 
17               17 17                 
18               18 18                 
19               19 19                 













From: E.M Masupye 
To: The participant 
Re: Invitation to participate in a study 
 
I, as a student in the Health Sciences, Pharmacy and Pharmacology Department,  
University of Kwa-Zulu Natal, Westville Campus, am involved in a study to evaluate 
the extemporaneous compounding in Polokwane hospital pharmacies. 
 
The procedure to be followed in this study is to administer a questionnaire to willing 
participants in order to assess the frequency, extent, nature and information related 
to extemporaneous preparations. The study will identify the types of 
extemporaneously prepared products compounded in Polokwane hospital 
pharmacies, the most frequently prepared product in those hospitals and the 
demographic data of the pharmacy personnel. 
I would like to invite you to participate in this research study. Please find attached a 
consent form. Participation is voluntary and you are free to withdraw from the study 
at any time. If at any stage you have queries or questions about the research, or 
would like to obtain more information about this study, please feel free to contact 




Tel: 015 268 2356/9 
 
School of Pharmacy and Pharmacology 













PARTICIPANT CONSENT FORM 
 
UNIVERSITY OF KWAZULU NATAL CONSENT FORM 
 
Statement concerning participation in a Research Project. 
 
Name of Project: 
 
Evaluation of extemporaneous compounding in hospital pharmacies in the Polokwane 
Municipality 
 
I have read the information on the Evaluation of extemporaneous compounding in hospital 
pharmacies in the Polokwane Municipality. I heard the aims and objectives of the proposed study 
and was provided the opportunity to ask questions and given adequate time to rethink the issue. The 
aim and objectives of the study are sufficiently clear to me.  I have not been pressurized to 
participate in any way. 
 
I understand that participation in this Project is completely voluntary and that I may withdraw from 
it at any time and without supplying reasons.  This will have no influence on the regular treatment 
that holds for my condition neither will it influence the care that I receive from my regular doctor. 
 
I know that this Project has been approved by the Research, Ethics and Publications Committee of 
Faculty of Health Sciences, University of Kwazulu Natal. I am fully aware that the results of this 
Project will be used for scientific purposes and may be published.  I agree to this, provided my 
privacy is guaranteed. 
 
I hereby give consent to participate in this Project. 
 
 
............................................................        ........................................................ 
Name of volunteer participant                               Signature of participant 
 
 
................................    ....................................    ................................................ 
Place.                             Date.                                Witness 
___________________________________________________________________________ 
Statement by the Researcher 
 
I provided verbal and/or written information regarding this Project 
I agree to answer any future questions concerning the Project as best as I am 
able. 
I will adhere to the approved protocol. 
 
 
.......................................    ....................................    ...............…… 









ANNEXURE 8: Map of the province (Mapsofworld.com) 
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